YH-013 is under clinical development by Eucure (Beijing) Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YH-013’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-013 overview
YH-013 is under development for the treatment of solid tumor, lung adenocarcinoma, non-small cell lung carcinoma and and human lung mucoepidermoid carcinoma. The therapeutic candidate is a bi-specific monoclonal antibody drug conjugate and is developed based on Bispecific Antibody Platform. It acts by targeting cells expressing topoisomerase I, EGFR and MET.
Eucure (Beijing) Biopharma overview
Eucure (Beijing) Biopharma is a biotechnology company that discovery and development of innovative immuno-oncology targeted antibodies. The company is headquartered China.
For a complete picture of YH-013’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
